![application/pdf](/modules/file/icons/application-pdf.png)
The HIV field has, by and large, acknowledged the necessity of addressing the structural barriers to effective HIV prevention and treatment. The question remains, however: how to pay for these efforts?
Examining synergies between the structural drivers of HIV and broader health and development goals, STRIVE researchers developed a co-financing mechanism to assess the cost-effectiveness of interventions that generate benefits across several sectors, and dividing the costs accordingly.
The Health Economics and Epidemiology Research Office (HE2RO) at the University of the Witwatersrand – commissioned to lead the modelling and costing of the South African HIV Investment Case – took up the co-financing approach and applied it in their modelling. Subsequently, the country’s National Strategic Plan (NSP) included exploring cross-department co-financing as an innovative financing strategy.